Advertisement

Current Dermatology Reports

, Volume 8, Issue 1, pp 1–5 | Cite as

Update on Risankizumab for Psoriasis

  • Jennifer C. BaresEmail author
  • Mark G. Lebwohl
Psoriasis (J Wu, Section Editor)
  • 15 Downloads
Part of the following topical collections:
  1. Topical Collection on Psoriasis

Abstract

Purpose of Review

This review highlights the latest data on risankizumab, including efficacy and safety data from recent clinical trials.

Recent Findings

In multiple phase 3 clinical trials, risankizumab was shown to be safe and efficacious. Risankizumab demonstrated superior efficacy to leading active comparators for the induction and maintenance of clear skin and was shown to have a safety profile similar to other biologic therapies currently on the market.

Summary

Targeted biologic medications for plaque psoriasis have provided insight into the complex immune pathways that are now understood to lead to the development of several autoimmune diseases including plaque psoriasis. Risankizumab, a novel, fully human monoclonal antibody against the IL-23p19 subunit, is currently under investigation for the treatment of moderate-to-severe plaque psoriasis and shows promise to provide complete and lasting skin clearance with convenient dosing for patients. Future studies are needed to explore the long-term safety and efficacy of risankizumab beyond 5 years of therapy.

Keywords

Psoriasis Risankizumab Biologic IL-23 Efficacy Safety 

Notes

Compliance with Ethical Standards

Conflict of Interest

Mark Lebwohl is an employee of Mount Sinai and receives research funds from: Abbvie, Amgen, Arcutis, Bausch Health (Valeant), Boehringer Ingelheim, Celgene, Eli Lilly, Incyte, Johnson & Johnson (Centocor, Janssen), Leo Pharmaceutucals, Medimmune/Astra Zeneca, Novartis, Pfizer (Anacor), Regeneron, Sciderm, UCB, Inc., and ViDac. Dr. Lebwohl is also a consultant for Allergan, Aqua, Arcutis, Inc., Boehringer-Ingelheim, Bristol-Myers Squibb, LEO Pharma, Menlo, Mitsubishi, Neuroderm, Promius/Dr. Reddy’s Laboratories, Theravance, and Verrica.

Dr. Bares has nothing to disclose.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871–81.CrossRefGoogle Scholar
  2. 2.
    Hawkes JE, Chan TC, Krueger JG. Psoriasis pathogenesis and the development of novel targeted immune therapies. J Allergy Clin Immunol. 2017;140(3):645–53.CrossRefGoogle Scholar
  3. 3.
    Pfohler C, Muller CS, Vogt T. Psoriasis vulgaris and psoriasis pustulosa - epidemiology, quality of life, comorbidities and treatment. Curr Rheumatol Rev. 2013;9(1):2–7.CrossRefGoogle Scholar
  4. 4.
    Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12):1664–75.CrossRefGoogle Scholar
  5. 5.
    Lebwohl MG. Biologics for psoriasis: a translational research success story. J Invest Dermatol. 2015;135(5):1205–7.CrossRefGoogle Scholar
  6. 6.
    Torres T. Selective interleukin-23 p19 inhibition: another game changer in psoriasis? Focus on Risankizumab. Drugs. 2017;77(14):1493–503.CrossRefGoogle Scholar
  7. 7.
    Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525–34.CrossRefGoogle Scholar
  8. 8.
    Piskin G, Sylva-Steenland RM, Bos JD, et al. In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin. J Immunol. 2006;176:1908–15.CrossRefGoogle Scholar
  9. 9.
    Fotiadou C, Lazaridou E, Sotiriou E, Ioannides D. Targeting IL-23 in psoriasis: current perspectives. Psoriasis (Auckl). 2018;8:1–5.Google Scholar
  10. 10.
    • Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2015;136(1):116–124.e7 This study demonstrated that risankizumab was well tolerated and associated with substantial clinical response at week 12 compared with placebo. CrossRefGoogle Scholar
  11. 11.
    •• Papp KA, Blauvelt A, Bukhalo M, et al. Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2017;376(16):1551–60 This study showed that risankizumab was well tolerated and associated with a clinical response superior to ustekinumab at 12 weeks. CrossRefGoogle Scholar
  12. 12.
    •• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–61 This study demonstrated the efficacy of risankizumab is more rapid and superior to that of ustekinumab through 1 year while having a similar safety profile and equally convenient dosing. CrossRefGoogle Scholar
  13. 13.
    Abbvie. Risankizumab meets all co-primary and ranked secondary endpoints, achieving significantly greater efficacy versus standard biologic therapies in three pivotal phase 3 trials. https://news.abbvie.com/news/risankizumab-meets-all-co-primary-and-ranked-secondary-endpoints-achieving-significantlygreater-efficacy-versus-standard-biologic-therapies-in-three-pivotal-phase-3-psoriasis-studies.htm. Published 26 October 2017. Accessed 30 August 2018.
  14. 14.
    Abbvie. Risankizumab meets all primary endpoints reporting positive results in fourth pivotal phase 3 psoriasis study. https://news.abbvie.com/news/press-releases/risankizumab-meets-all-primary-endpoints-reporting-positive-results-in-fourth-pivotal-phase-3-psoriasisstudy.htm. Published 4 December 2017. Accessed 30 August 2018.
  15. 15.
    Abbvie. Abbvie submits biologics license application to U.S. FDA for investigational treatment risankizumab for moderate to severe plaque psoriasis. https://news.abbvie.com/news/abbvie-submits-biologics-license-application-to-us-fda-for-investigational-treatment-risankizumab-for-moderate-to-severeplaque-psoriasis.htm. Published 25 April 2018. Accessed 30 August 2018.
  16. 16.
    Feagan BG, Sandborn WJ, D'haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–709.CrossRefGoogle Scholar
  17. 17.
    Baeten D, Østergaard M, Wei JC, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis. 2018;77(9):1295–302.CrossRefGoogle Scholar
  18. 18.
    Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53.CrossRefGoogle Scholar
  19. 19.
    Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27–40.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of DermatologyIcahn School of Medicine at Mount SinaiNew YorkUSA

Personalised recommendations